Key result
Complete monitoring of stage 3 chronic kidney disease was performed in only 25% of patients overall, but was more likely in patients with concomitant diabetes.
Why the study?
Kidney Health Australia recommends regular monitoring of CKD patients to reduce progression and prevent complications, but how general practice aligns with these guidelines was unexamined.
How does clinical practice align with Kidney Health Australia's CKD monitoring guidelines in adults with stage 3 CKD?
Observational (n=19,712)
Yes
How does clinical practice align with Kidney Health Australia's CKD monitoring guidelines in adults with stage 3 CKD?
Adherence to CKD monitoring guidelines in Australian general practice is low, particularly for albuminuria, highlighting a gap in preventive care.
Answers are grounded in this paper and cite their sources.
CKD monitoring gaps in Australian general practice warrant quality improvement; leaves open which interventions best close adherence shortfalls.
BACKGROUND AND OBJECTIVES: Kidney Health Australia recommends regular monitoring of patients with chronic kidney disease (CKD) to reduce progression and prevent complications such as cardiovascular disease. The objective of this study was to examine how practice aligns with the recommendations in Kidney Health Australia's CKD guidelines. METHOD: Australian general practice data from the NPS MedicineWise MedicineInsight program (1 January 2013 - 1 June 2016) for 19,712 adults with laboratory evidence of stage 3 CKD were analysed. Complete monitoring in these individuals was defined as having at least one recorded assessment of blood pressure, urine albumin-to-creatinine ratio, estimated glomerular filtration rate and serum lipids over an 18-month period. RESULTS: Complete monitoring was performed for 25% of the cohort; 54.9% among patients with concomitant diabetes and 14.1% among patients without diabetes. Patients with diabetes, hypertension and a documented diagnosis of CKD were more likely to have complete monitoring. DISCUSSION: There is room for improvement in monitoring of patients with stage 3 CKD, particularly for albuminuria, which was monitored in fewer than 50% of these patients.
No takes yet. Share an insight, caveat, or question.
Khanam et al. (2019) conducted an observational in Stage 3 chronic kidney disease (n=19,712). Concomitant diabetes vs. No concomitant diabetes was evaluated on Complete monitoring (at least one recorded assessment of blood pressure, urine ACR, eGFR, and serum lipids over 18 months) (OR 7.37, 95% CI 6.83-7.95, p=<0.0001). Complete monitoring of stage 3 chronic kidney disease was performed in only 25% of patients overall, but was more likely in patients with concomitant diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: